Chemicalinfo Chemlink Pharm-Chem Net

Cancer drug puts licence, patent rules to test THE drugs manufacturing industry is on a state of alert following two landmark developments over a cancer treatment medicine.   ...

Scrip Yearbook 2008 Charts the Progress of the Pharmaceutical Industry as Reported in Scrip World Pharmaceutical News over the 12 Months up to the End of November 2007  DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researcha...

AZT, 3TC and efavirenz: a tolerable first-line regimen for South African men Derek Thaczuk, Monday, January 07, 2008 The safety and tolerability of a first-line regimen of AZT, 3TC and efavirenz has been assessed in ...

India can dominate global pharma landscapeBy staff reporter07/01/2008 - Although India 'has carved out a significant portion of the world pharma pie', an enormous change in mindset is needed if the country is to become a global pharmaceutical hub, ac...

WuXi PharmaTech makes its first acquisitionBy Kirsty Barnes07/01/2008 - WuXi PharmaTech, China's contract research titan, has orchestrated its first acquisition, gaining biologics capabilities and a base in the US. The firm has agreed to pay $151m fo...

Ractopamine is a phenolethanolamine beta-adrenoceptor agonist that is used for the improvement of weight gain, carcass leanness and feed efficiency in pigs. Ractopamine is marketed as the hydrochloride with a minimal purity of 92% and exists in two diastereomeric forms which are identified as RS, SR and RR, SS. The RR-isomer, butopamine, is a potent cardiotonic in humans. Ractopamine hydrochloride had not been previously evaluated by the Joint FAO/WHO Expert Committee on Food Additives.
Clorhidrato del Ractopamine, Ractopamine hydrochloride, Cas number: 90274-24-1......

Abstract

Background. Vatalanib (PTK787/ZK 222584) is an orally active and selective inhibitor of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. A phase I/II study examined the safety and response profile of vatalanib in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC).
Patients and Methods. Patients with previously untreated, inoperable, measurable, advanced-stage CRC were administered escalating doses of vatalanib (500-2000 mg/day p.o.) in 42-day cycles. The FOLFOX4 regimen was coadministered with vatalanib, and treatment was continued until disease progression or unacceptable toxicity occurred. Tumor response was assessed every 12 weeks.

Imatinib (Gleevec ®) Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred...

Erlotinib (Tarceva®) Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.Similar to gefitinib, erlo...

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).